Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3814679 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8063898 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL5203537 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6956648 | 0.87 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL8063904 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL6953718 | 0.86 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL6961287 | 0.86 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL6962439 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL6962469 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL5205468 | 0.85 | PTGS1 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| EP-1061908-A4 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2005-01-06 | — | — | US | claimed |
| US-20040192694-A1 | Use of COX-2 inhibitors as gastroprokinetics | MANGEL ALLEN WAYNE (US) | 2004-09-30 | — | — | US | claimed |
| EP-1024696-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | claimed |
| EP-1349548-A4 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO INC (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | HARTMAN GEORGE D (US) | 2004-03-18 | — | — | US | claimed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1349548-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | Merck & Co., Inc. (US) | 2003-10-08 | — | — | EP | claimed |
| WO-2001056573-A1 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| US-6245797-B1 | ADMINISTERING MIXTURE OF ENZYME INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | claimed |
| US-6184248-B1 | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-02-06 | — | — | US | claimed |
| EP-1061908-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| EP-1024696-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | Merck & Co., Inc. (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| WO-1999020110-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | claimed |
| CN-1200119-A | (METHYLSULFONYL) PHENYL-2- (5H) -FURANONE AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 1998-11-25 | — | — | CN | claimed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | claimed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192694-A1 | Use of COX-2 inhibitors as gastroprokinetics | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 5/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 1/4885 |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | TNF, PTGS1, MIF | PTGS2 4/4885PTGS1 2/4885 |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGB5 | PTGS2 27/4885PTGS1 36/4885 |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | ITGB3, ITGB5, ITGB2 | PTGS2 27/4885PTGS1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.